Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 866M 759M 701M 645M 1.22B 83.47B 1.24B 8.39B 3.29B 40.84B 3.25B 3.18B 141B P/E 2026 *
14.6x
P/E 2027 * 11.2x
Enterprise Value 1.18B 1.03B 953M 876M 1.65B 113B 1.68B 11.4B 4.47B 55.5B 4.42B 4.32B 191B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.33x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.58%
1 week+1.76%
Current month-2.73%
1 month+4.36%
3 months-14.35%
6 months-24.35%
Current year-26.70%
1 week 18.83
Extreme 18.83
20.35
1 month 18.22
Extreme 18.22
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
9/7/26 Free

Director

24,532 0.0556%
2/6/26 Tax

Director

-769 0.0017%
1/6/26 Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%+1.76%-4.80%-68.96% 871M
-2.73%-2.96%+48.62%+147.27% 1,051B
-1.67%-3.47%+52.00%+47.77% 609B
-0.44%+2.17%+33.88%+78.20% 450B
-0.75%+0.30%+28.32%+21.15% 330B
-1.52%-1.19%+33.38%+35.35% 284B
-1.70%-1.82%+20.26%+15.74% 263B
-0.58%+1.11%-20.89%-40.59% 223B
-0.58%+1.03%+23.55%+56.14% 198B
-0.80%+1.38%+23.09%+66.64% 167B
Average -0.74%+0.41%+23.74%+35.87% 357.59B
Weighted average by Cap. -0.89%-1.07%+35.24%+70.85%

Financials

2026 *2027 *
Net sales 746M 654M 605M 556M 1.05B 71.97B 1.07B 7.23B 2.83B 35.22B 2.8B 2.74B 121B 779M 683M 631M 581M 1.1B 75.15B 1.11B 7.55B 2.96B 36.77B 2.93B 2.86B 127B
Net income 64M 56.1M 51.85M 47.69M 89.98M 6.17B 91.42M 620M 243M 3.02B 240M 235M 10.4B 84M 73.63M 68.06M 62.59M 118M 8.1B 120M 814M 319M 3.96B 315M 309M 13.65B
Net Debt 311M 272M 252M 232M 437M 29.97B 444M 3.01B 1.18B 14.66B 1.17B 1.14B 50.51B 173M 152M 141M 129M 244M 16.72B 248M 1.68B 659M 8.18B 651M 637M 28.19B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
20/07/26 USD 19.63 -0.58% 437,415
17/07/26 USD 19.75 -0.58% 338,457
16/07/26 USD 19.86 +2.37% 416,861
15/07/26 USD 19.40 +3.16% 356,089
14/07/26 USD 18.81 -2.51% 334,748
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
19.63USD
Average target price
22.00USD
Spread / Average Target
+12.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock